High-sensitivity C-reactive protein and liver enzymes in individuals with Metabolic Syndrome in Talca, Chile

Leiva,E.; Mujica,V.; Palomo,I.; Orrego,R.; Guzman,L.; Nuñez,S.; Moore-Carrasco,R.; Icaza,G.; Diaz,N.

doi:10.3892/etm_00000028

High-sensitivity C-reactive protein and liver enzymes in individuals with Metabolic Syndrome in Talca, Chile

Authors:
- E. Leiva
- V. Mujica
- I. Palomo
- R. Orrego
- L. Guzman
- S. Nuñez
- R. Moore-Carrasco
- G. Icaza
- N. Diaz
View Affiliations

Affiliations: Department of Clinical Biochemistry and Immunohematology, Health Science Faculty, Universidad de Talca, Talca, Chile. eleivam@utalca.cl
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000028
Pages: 175-179

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metabolic syndrome (MS) is a core set of disorders, including abdominal obesity, dyslipidemia, hypertension and hypertriglyceridemia that together predict the development of diabetes type 2 and cardiovascular disease. This study investigated the relationship between liver enzyme levels and high-sensitivity C-reactive protein (hs-CRP) in subjects with and without MS. Alanine-aminotransferase (ALAT), aspartate-aminotransferase (ASAT), γ-glutamyl transferase (GGT) and hs-CRP were measured in 510 subjects, aged 40 to 65 years old. Patients were selected from 1007 subjects from the Research Program for Cardiovascular Disease Risk Factors in Talca, Chile. Results showed that women with MS presented higher liver enzyme levels than those who did not have MS. This was not observed in male patients for the enzymes ALAT and ASAT. However, GGT and hs-PCR levels were higher in male and female patients with MS than in those without MS. In conclusion, it is important to search for the presence of MS when diagnosing fatty liver. Moreover, the presence of liver disease in patients with MS should be further investigated.

View Figures

View References

1.	Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr and Haffner SM: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 54:3140–3147. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Mulhall BP, Ong JP and Younossi ZM: Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 17:1136–1143. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Angulo P and Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 17:S186–S190. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Grant LM and Lisker-Melman M: Nonalcoholic fatty liver disease. Ann Hepatol. 3:93–99. 2004.PubMed/NCBI
5.	Diehl AM, Goodman Z and Ishak KG: Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 95:1056–1062. 1988.PubMed/NCBI
6.	Bellentani S, Saccoccio G, Masutti F, et al: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 132:112–117. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Akbar DH and Kawther AH: Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 26:3351–3352. 2003. View Article : Google Scholar
8.	Gupte P, Amarapurkar D, Agal S, et al: Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 19:854–858. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Assy N, Kaita K, Mymin D, Levy C, Rosser B and Minuk G: Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 45:1929–1934. 2000. View Article : Google Scholar
10.	Donati G, Stagni B, Piscaglia F, et al: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 53:1020–1023. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1595–1607. 1988. View Article : Google Scholar : PubMed/NCBI
12.	Neuschwander-Tetri BA and Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 37:1202–1219. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Preuss HG: Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr. 16:397–403. 1997. View Article : Google Scholar : PubMed/NCBI
14.	Balaban YH, Sumer H, Simsek H, Us D and Tatar G: Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann Hepatol. 5:109–114. 2006.PubMed/NCBI
15.	Lee DH, Ha MH, Kim JH, et al: Gamma-glutamyltransferase and diabetes – a 4 year follow-up study. Diabetologia. 46:359–364. 2003.
16.	Czaja MJ: Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology. 40:19–22. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Matsuzawa Y, Funahashi T and Nakamura T: Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci. 892:146–154. 1999. View Article : Google Scholar : PubMed/NCBI
18.	Day CP and James OF: Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 114:842–845. 1998.
19.	Gentile CL and Pagliassotti MJ: The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem. 19:567–576. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Mehta K, van Thiel DH, Shah N and Mobarhan S: Non-alcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 60:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Fain JN, Madan AK, Hiler ML, Cheema P and Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 145:2273–2282. 2004. View Article : Google Scholar : PubMed/NCBI
22.	Kershaw EE and Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89:2548–2556. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama. 285:2486–2497. 2001. View Article : Google Scholar
24.	Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res. 6(Suppl 2): S51–S209. 1998.PubMed/NCBI
25.	The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 157:2413–2446. 1997. View Article : Google Scholar
26.	Marchesini G, Avagnina S, Barantani EG, et al: Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 28:333–339. 2005. View Article : Google Scholar : PubMed/NCBI
27.	James OF and Day CP: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 29:495–501. 1998. View Article : Google Scholar : PubMed/NCBI
28.	Lee YS, Kek BL, Poh LK, Saw SM and Loke KY: Association of raised liver transaminases with physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese children. J Pediatr Gastroenterol Nutr. 47:172–178. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Nannipieri M, Gonzales C, Baldi S, et al: Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 28:1757–1762. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Medina J, Fernandez-Salazar LI, Garcia-Buey L and Moreno-Otero R: Approach to the pathogenesis and treatment of non-alcoholic steatohepatitis. Diabetes Care. 27:2057–2066. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Yavuz BB, Yavuz B, Halil M, et al: Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer's disease. Int Psychogeriatr. 20:815–823. 2008.PubMed/NCBI
32.	Karp DR, Shimooku K and Lipsky PE: Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem. 276:3798–3804. 2001. View Article : Google Scholar : PubMed/NCBI